NEW YORK, Oct. 9, 2014 /PRNewswire/ -- Harwood Feffer LLP
(www.hfesq.com) is investigating potential claims against the board
of directors of Durata Therapeutics, Inc. ("Durata" or the
"Company") (NASDAQ: DRTX) concerning the proposed acquisition of
the Company by Actavis plc ("Actavis").
Under the terms of the transaction, Actavis would acquire Durata
in a transaction valued at approximately $675 million. Durata shareholders are being
offered $23.00 in cash plus the right
to receive a payment of as much as $5.00 per share if certain milestones are
achieved. According to Yahoo! Finance, at least one analyst
has set a price target for Durata stock of $26.00 per share.
Our investigation concerns whether the Durata board of directors
is fulfilling its fiduciary duties, maximizing the value of the
Company, disclosing all material benefits and costs, and obtaining
full and fair consideration for Company stockholders.
If you own Durata shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Benjamin I. Sachs-Michaels,
Esq.
Robert I. Harwood, Esq.
Craig Lowther
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
Logo -
http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
SOURCE Harwood Feffer LLP